Evidence map›Paper›PMID 40688438›Full record

ArticleJAAD international2025

Efficacy and safety of oral upadacitinib-topical ruxolitinib combination therapy in the treatment of progressive nonsegmental vitiligo.

Weiran Li, Jinping Gao, He Huang, Tingting Zhu, Xianfa Tang, Ruochen Zhang, Xiaojian Chen, Yang Wang, Yaohua Zhang, Xuejun Zhang and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JAAD international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Topical ruxolitinib ± oral baricitinib in the treatment of active non-segmental vitiligo: A retrospective analysis.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026
    Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Weiran LiDepartment of Dermatology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Jinping GaoDepartment of Dermatology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
He HuangDepartment of Dermatology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Tingting ZhuDepartment of Dermatology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Xianfa TangDepartment of Dermatology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Ruochen ZhangDepartment of Dermatology, The Fourth Affiliated Hospital of Soochow University (Suzhou Dushu Lake Hospital), Medical Center of Soochow University, Suzhou, Jiangsu, China.
Xiaojian ChenDepartment of Dermatology, The Fourth Affiliated Hospital of Soochow University (Suzhou Dushu Lake Hospital), Medical Center of Soochow University, Suzhou, Jiangsu, China.
Yang WangDepartment of Dermatology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Yaohua ZhangDepartment of Dermatology, Institute of Dermatology, Huashan Hospital, Fudan University, Shanghai, China.
Xuejun ZhangDepartment of Dermatology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Yong CuiDepartment of Dermatology, China-Japan Friendship Hospital, Beijing, China.
Youwen ZhouDepartment of Dermatology and Skin Science, University of British Columbia, Vancouver, Canada.
Bo ZhangDepartment of Dermatology, The Fourth Affiliated Hospital of Soochow University (Suzhou Dushu Lake Hospital), Medical Center of Soochow University, Suzhou, Jiangsu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

combination therapyefficacyJAK inhibitornonsegmental vitiligoprogressiveruxolitinibupadacitinib

Identifiers

PMID40688438
PMCPMC12271499

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.